Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Monday woes were shared by Bristol Myers Squibb and Synairgen, as their clinical trial candidates failed to perform as expected.
Clay Siegall resigned his role as president, CEO and a member of the board of directors of Seagen following domestic violence allegations. Roger Dansey will serve as interim CEO.
Researchers released a study that has identified the first biochemical marker that could help detect babies more at risk of Sudden Infant Death Syndrome (SIDS) while they are alive.
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.
With data siloed with various researchers and departments, it is broadly inaccessible and eventually forgotten. Digital management has become the new bottleneck in biotech development.
In addition to lowering of blood sugar, Mounjaro also enabled patients to lower their weight by 15 to 23 pounds. The drug compared well to other diabetes medications including Novo Nordisk’s semaglutide.
A study by researchers at the Massachusetts Institute of Technolog (MIT) have found a brain circuit in the anterior thalamus that is critical for memory function.
U.S. Food and Drug Administration(FDA) has granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
The U.S. Food and Drug Administration (FDA) has approved Mitsubishi Tanabe Pharma America’s oral alternative to its own treatment for amyotrophic lateral sclerosis (ALS).
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio’s pediatric methylmalonic acidemia study is back up and running and another look at Roche’s TIGIT flop.
Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
Elon Musk’s Neuralink has been beaten to the clinic by rival brain-computer interface company Synchron which is assessing its implant in individuals with severe paralysis.
